"New Migraine Drug Offers Unprecedented Relief, But Some Insurance Plans Don’t Cover It"
A new group of injectable drugs inhibit a protein thought to trigger migraines, but not all insurance plans cover it -- and many people can’t afford the $575 a month price tag. Tara Thorn, 39 suffered from 30 migraines a month before taking Aimovig, which reduced her migraines significantly. As a public school teacher, she can’t afford Aimovig, which was recently denied by her insurance company. According to Lauren Natbony, MD, assistant professor of neurology at the Icahn School of Medicine at Mount Sinai, “I’ve had patients come into my office crying saying, this changed my life, don’t take this away from me.” She added, “If we think about the overall healthcare costs, these medications are changing that.”
— Lauren R. Natbony, MD, Assistant Professor, Neurology, Icahn School of Medicine at Mount Sinai